Urine test detects bladder cancer: study
Posted on: Tuesday, 25 October 2005, 15:11 CDT
CHICAGO (Reuters) - A simple and accurate urine test can detect bladder cancer early and should be used on smokers and others prone to the disease, Italian researchers said on Tuesday.
The test for the enzyme telomerase in urine was found to be accurate some 90 percent of the time in men, after the cancer diagnoses were confirmed with standard invasive examinations of the bladder and urinary tract. The test also detected low-grade tumors, when the disease was in its infancy.
When bladder cancer -- which afflicts 60,000 Americans annually and kills 20 percent of patients -- is caught early, treatment is usually more effective, researchers from Morgagni-Pierantoni Hospital in Forli, Italy, wrote in the Journal of the American Medical Association.
Despite the demonstrated accuracy of the test in a small study of 218 male patients, the researchers said further study was needed for what is a promising diagnostic tool.
"It is not recommended for use in routine screening programs because of the low incidence of bladder cancer, and should be aimed at high-risk sub-groups. Specifically, smokers have about a three-fold increased risk of developing bladder cancer compared to nonsmokers," study author Maria Aurora Sanchini wrote.
Source: REUTERS
Related Articles
- Data From Three Clinical Studies of bioTheranostics' Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
- Prostate cancer urine test being developed
- Previstage(TM) GCC Colorectal Cancer Staging Test Featured in Expert Reviews Article
- LabCorp Introduces New Cancer Diagnostic Test
- Genetic Map of a Cancerous Bladder Created
- Miraculins Files Pre-IDE for Prostate Cancer Diagnostic Test
- Kaiser Permanente Study Shows Under-Used Colon Cancer Screening Test is Effective
- Ciphergen Initiates Clinical Trial for Ovarian Cancer Triage Test
- More Than Half of Survey Respondents Said They Are Concerned With the Accuracy of Prostate Cancer Screening Tests
- Agendia's MammaPrint(R) Shows Significant Agreement With Other Multi-Gene Breast Cancer Prognosis Tests
User Comments (0)

RSS Feeds